ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 145 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47,811,932 | -39.6% | 6,979,844 | -8.6% | 0.01% | -33.3% |
| Q2 2023 | $79,204,691 | +32.8% | 7,637,868 | +3.6% | 0.02% | +25.0% |
| Q1 2023 | $59,644,342 | -30.9% | 7,372,601 | +34.4% | 0.01% | -29.4% |
| Q4 2022 | $86,373,206 | +58.9% | 5,484,013 | +58.8% | 0.02% | +41.7% |
| Q3 2022 | $54,364,000 | -20.5% | 3,453,853 | -29.5% | 0.01% | -14.3% |
| Q2 2022 | $68,422,000 | -30.7% | 4,901,263 | -14.5% | 0.01% | -17.6% |
| Q1 2022 | $98,789,000 | +22.7% | 5,730,253 | +3.4% | 0.02% | +30.8% |
| Q4 2021 | $80,540,000 | -17.5% | 5,539,268 | +2.2% | 0.01% | -23.5% |
| Q3 2021 | $97,568,000 | +18.3% | 5,420,453 | +15.4% | 0.02% | +21.4% |
| Q2 2021 | $82,492,000 | +293.8% | 4,697,749 | +465.1% | 0.01% | +250.0% |
| Q1 2021 | $20,950,000 | +3530.8% | 831,329 | +2427.3% | 0.00% | – |
| Q1 2018 | $577,000 | – | 32,894 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |